Hypertrophic Scar Treatment
OLX101A is designed to suppress the formation of hypertrophic scars / keloids caused by damage to the dermis and excessive production of collagen fibers. Unlike conventional surgical treatments which are not involved in car formation mechanisms, OLX101AIt directly inhibits collagen production by targeting CTGF mRNA.
Target RNA: CTGF
Administration Route: Intradermal Injection
CTGF is a major factor in fibrotic diseases which promotes the production of extracellular matrix (ECM) proteins, including collagen.
Often, abnormal response (production of extra collagen fibers due to overexpression of CTGF) during the wound healing process leads to the formation of hypertrophic scars/keloids
- Efficient inhibition of fibrosis identified in animal models
- Phase 1 clinical trial completed (US, UK)
제목 링크 A Randomized, Single Blind, Single Dose, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Intradermal Dosage Form of BMT101 in Healthy Male Volunteers Learn More A Phase 1, Single Center, Placebo-controlled, Interventional Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles in Healthy Subjects Compared to Placebo Learn More
- Phase 2 clinical trial in progress (Korea, US)
Title Link An Independent Evaluator-Blind, Dose-Escalation, Untreated-Controlled, Within-Subject, Phase 2a Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of BMT 101 Administration for the Prevention of Hypertrophic Scar Learn More Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery Learn More
- 2016 Journal of Investigative Dermatology
Title Download Hwang, J., Chang, C., Kim, J. H., Oh, C. T., Lee, H. N., Lee, C., Oh, D., Lee, C., Kim, B., Hong, S. W., & Lee, D. K. (2016). Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor. Journal of Investigative Dermatology, 136(11), 2305-2313. PDF Download
- 2021 OTS (Oligonucleotide Therapeutics Society) (Sep. 2021)